Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients

Clinical Cancer Research

Volumn 4, Issue 4, 1998, Pages 941-948

  Reigner, Bruno ^a   Verweij, Jaap ^c   Dirix, Luc ^d   Cassidy, Jim ^e   Twelves, Christopher ^f   Allman, David ^g   Weidekamm, Erhard ^a   Roos, Brigitte ^a   Banken, Ludger ^a   Utoh, Masahiro ^b   Osterwalder, Bruno ^g  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b NIPPON ROCHE RESEARCH CENTER   (Japan)

^c ERASMUS MC CANCER INSTITUTE   (Netherlands)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^f BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^g IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FLUORO BETA ALANINE; CAPECITABINE; FLUOROURACIL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; FEMALE; FOOD DRUG INTERACTION; FOOD INTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; COLORECTAL NEOPLASMS; CROSS-OVER STUDIES; DEOXYCYTIDINE; DOUBLE-BLIND METHOD; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED;

EID: 14444280873     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Kemeney, N. Current approaches to metastatic colorectal cancer. Semin. Oncol., 21 (Suppl. 7): 67-75, 1994.
2. Poon, M. A., O'Connell, M. J., Wieand, H. S., Cullinan, S. A., Everson, L. K., Krook, J. E., Mailliard, J. A., Laurie, J. A., Tschetter, L. K., and Weisenfeld, M. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J. Clin. Oncol., 9: 1967-1972, 1991.
3. Arbuck, S. G. Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer (Phila.), 63: 1036-1044, 1989.
4. Schueller, J., Cassidy, J., Reigner, B., Durston, S., Roos, B., Ishitsuka, H., Utoh, M., and Dumont, E. Tumor selectivity of Xeloda in colorectal cancer patients. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 16: 227, 1997.
5. Diasio, R. B., and Harris, B. E. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet., 16: 215-237, 1989.
6. Twelves, C., Budman, D. R., Creavan, P. J., Schellens, J. H. M., Kuruma, I., Dumont E., Osterwalder, B., and Reigner, B. G. Pharmacokinetics and pharmacodynamics of capecitabine in two phase 1 studies. Proc. Am. Soc. Clin. Oncol., 15: 1509, 1996.
7. Hughes, M., Planting, A., Twelves, C., Schellens, J., Allman, D., Osterwalder, B., Kaye, S., and Verweij, J. A Phase 1 study of intermittent twice daily oral therapy with capecitabine in patients with advanced and/or metastatic solid tumor. NCI-EORTC Symposium on New Drugs in Cancer Therapy, Vol. 7, p. 87, 1996.
8. Meropol, N. G., Budman, D. R., Creavan, P. J., Lichtman, S., Berghorn, E., Behr, J., Gordon, R. J., and Osterwalder, B. A Phase 1 study of continuous twice daily treatment with capecitabine in patients with advanced and/or metastatic solid tumors. NCI-EORTC Symposium on New Drugs in Cancer Therapy, Vol. 7, p. 87, 1996.
9. Bajetta, E., Colleoni, M., Di Bartolomeo, M., Buzzoni, R., Bozzetti, F., Doci, R., Somma, L., Cappuzzo, F., Stampino, C. G., Guenzi, A., Balant, L., Zilembo, N., and Di leo, A. Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. J. Clin. Oncol., 13: 2613-2619, 1995.
10. De Cesare, M., Pratesi, G., De Braud, F., Zunino, F., and Stampino, C. Remarkable antitumor activity of 5′-deoxy-5-fluorouridine in human colorectal tumor xenografts. Anticancer Res., 14: 549-554, 1994.
11. 4-trimethoxybenzoyl-5′-deoxy-5-fluorocytidine and its parent drug 5′-deoxy-5-fluorouridine. Chem. Pharm. Bull., 38: 998-1003, 1990.
12. De Bruijn, E. A., van Oosterom, A. T., Tjaden, U. R., Reeuwijk, H. J. E. M., and Pinedo, H. M. Pharmacology of 5′-deoxy-5-fluorouridine in patients with resistant ovarian cancer. Cancer Res., 45: 5931-5935, 1985.
13. De Bruijn, E. A., van Oosterom, A. T., and Tjaden, U. R. Site-specific delivery of 5-fluorouracil with 5-deoxy-5-fluorouridine. Regional Cancer Treatment, 2: 61-76, 1989.
14. Findlay, M., Van Cutsem, E., Kocha, W., Allman, D., Laffranchi, B., Griffin, T., Osterwalder, B., Dalley, D., Pazdur, R., and Verweij, J. A randomized Phase II study of Xeloda (capecitabine) in patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol., 16: 227, 1997.
15. Gibaldi, M., and Perrier, D. (eds.), Pharmacokinetics, Ed. 2. New York: Marcel Dekker, Inc., 1982.
16. Budman, D. R., Meropol, N. J., Reigner, B., Creavan, P. J., Lichtman, S. M., Berghorn, E., Behr, J., Gordon, R. J., Osterwalder, B., and Griffin, T. Preliminary studies of an oral fluoropyrimidine: capecitabine (Xeloda). J. Clin. Oncol., in press, 1998.
17. Gibaldi, M. Gastrointestinal absorption - biologic considerations. In: M. Gibaldi (ed.), Biopharmaceutics and Clinical Pharmacokinetics, Ed. 4, pp. 32-36. Malvern: Lea & Febiger, 1991.
18. Reigner, B. G., Jones, G. R., Cassidy, J., Schüller, J., Goggin, T., Jones, D., and Twelves, C. Hepatic dysfunction due to liver metastasis does not affect the bioactivation of capecitabine. Proc. Am. Soc. Clin. Oncol., in press, 1998.
19. Taguchi, T., Ishitani, K., Kurihara, M., Tominaga, T., Fukuyama, Y., Saigenji, K., Toge, T., Takashima, S., Sugimachi, K., and Hara, Y. A Japanese Phase 1 study of continuous twice daily treatment with capecitabine in patients with advanced and/or metastatic solid tumors. NCI-EORTC Symposium on New Drugs in Cancer Therapy, Vol. 7, p. 87, 1996.
20. Inaba, M., Mittsuhashi, J., and Osawa, S. Kinetic analysis of 5-fluorouracil action against various cancer cells. Jpn. J. Cancer Res., 81: 1039-1044, 1990.
21. Moore, M. J., and Theissen, J. J. Cytotoxics and irreversible effects. In: C. J. van Boxtel, N. H. G. Holford, and M. Danhof (eds.), The In Vivo Study of Drug Action, p. 379. Amsterdam: Elsevier, 1992.
22. Lindahl, A., Ungell, A. L., Knutson, L., and Lennernas, H. Characterization of fluids from the stomach and proximal jejunum in men and women. Pharm. Res. (NY), 14: 497-502, 1997.